/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Over the past four decades, Hyderabad-based Dr. Reddy’s Laboratories has earned phenomenal success in the global market. The drugmaker was the eighth largest generics player in the US as of 31 March 2024, sitting snugly with the likes of Sun Pharmaceutical Industries, Cipla and Lupin. Things on the home turf haven’t been as exciting though, with the company ranking 10th in terms of revenue. But that’s about to change.
Dr Reddy’s is now gunning for the fifth spot in the league table. Not just that. It wants to get there in just five years. “India remains a strategic priority for …
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
